| Trial | control | p<0.05 | harm | NS |
|---|
| CDPA, 1976 | aspirin vs placebo | | | Total mortality 0.70 [0.48; 1.01] Cardiovascular death 0.70 [0.47; 1.02] Non-fatal MI 0.89 [0.54; 1.46] |
| Cardiff I, 1974 | aspirin vs placebo | | | Total mortality 0.74 [0.52; 1.05] |
| Cardiff II, 1979 | aspirin vs placebo | | | Total mortality 0.83 [0.65; 1.05] |
| Vogel, 1979 | aspirin vs placebo | Cardiovascular death 0.50 [0.27; 0.92] Fatal MI 0.38 [0.17; 0.85] Non-fatal MI 0.47 [0.29; 0.75] | | Total mortality 0.68 [0.44; 1.05] |
| AMIS, 1980 | aspirin vs placebo | Non-fatal MI 0.78 [0.63; 0.96] | | Total mortality 1.11 [0.94; 1.32] |
| GAMIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.51; 1.34] Fatal MI 0.49 [0.17; 1.41] Non-fatal MI 0.71 [0.33; 1.53] |
| PARIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.59; 1.13] Cardiovascular death 0.82 [0.58; 1.17] Non-fatal MI 0.70 [0.48; 1.03] |
| JAMIS, 1999 | aspirin vs placebo | Non-fatal MI 0.27 [0.10; 0.72] | | Total mortality 1.18 [0.45; 3.12] Cardiovascular death 1.10 [0.34; 3.57] |
| Trial | Treatments | Patients | Method |
|---|
| CDPA, 1976 | Aspirin (324 mg) 3x/d (n=758) vs. Placebo (n=771) | MI survivors | Double blind Parallel groups Sample size: 758/771 Primary endpoint: No primary outcome clearly defined FU duration: 1.83 y |
| Cardiff I, 1974 | Aspirin (300 mg) 1x/d (n=615) vs. Placebo (n=624) | MI survivors | Double blind Parallel groups Sample size: 615/624 Primary endpoint: Total mortality FU duration: 2 years |
| Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year (n=832) vs. Placebo (n=850) | patients with myocardial infarction | Double blind Parallel groups Sample size: 832/850 Primary endpoint: Total mortality FU duration: 1 y |
| Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
(n=672) vs. Placebo
(n=668) | | Double blind Parallel groups Sample size: 672/668 Primary endpoint: Death or reinfraction FU duration: 1.75 y (mean) |
| AMIS, 1980 | Aspirin (500 mg) 2x/d for at least 3 years (n=2267) vs. Placebo (n=2257) | men and women who had had a documented myocardial infarction | Double blind Parallel groups Sample size: 2267/2257 Primary endpoint: Total mortality FU duration: > 3 y |
| GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years (n=317) vs. Placebo (n=309) | patients who had survived a myocardial infarction for 30-42 days | Double blind Parallel groups Sample size: 317/309 Primary endpoint: No primary outcome clearly defined FU duration: 2 y part of a 3-group trial |
| PARIS, 1980 | Aspirin (324 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 mo part of 3-group trial |
| JAMIS, 1999 | Aspirin (81 mg) 1x/d (n=250) vs. No antiplatelets (n=230) | patients with AMI within 1 month from the onset of symptoms | Open Parallel groups Sample size: 250/230 Primary endpoint: No primary outcome clearly defined FU duration: 1.3 y (mean) part of a 3-group trial |
